Veradermics' oral minoxidil clears late-stage trial endpoints

Veradermics, a Connecticut‑based biotech, reported that its oral extended‑release formulation of minoxidil, VDPHL01, has completed a late‑stage clinical trial. The drug is a pill version of the well‑known topical hair‑regrowth product Rogaine.

The company said the study met all of its primary and secondary endpoints, demonstrating that the oral formulation effectively promotes hair growth in participants. No safety concerns were highlighted in the brief report.

The positive readout positions Veradermics to advance the product toward regulatory submission and could broaden treatment options for patients with hair loss, pending further development steps.